Resource Library
Overcoming challenges to high-concentration formulation development
How can high-concentration biologics be formulated to enhance stability, manufacturability, and patient convenience?
With increasing demand for high-concentration antibodies, developers must address challenges such as viscosity, phase separation, and protein aggregation—all of which can impact formulation performance and production.
Our latest whitepaper explores these complexities and how the S-HiCon™ platform applies advanced analytical techniques and risk mitigation strategies to optimize high-concentration formulations.
How can high-concentration biologics be formulated to enhance stability, manufacturability, and patient convenience?
With increasing demand for high-concentration antibodies, developers must address challenges such as viscosity, phase separation, and protein aggregation—all of which can impact formulation performance and production.
Our latest whitepaper explores these complexities and how the S-HiCon™ platform applies advanced analytical techniques and risk mitigation strategies to optimize high-concentration formulations.